Glycolysis is an important metabolic pathway for most organisms, including protozoan parasites. Many of
these primitive eukaryotes have streamlined their metabolism, favoring glycolysis for generating ATP in the glucose-rich
environments in which they reside. Therefore, the enzymes involved in hexose metabolism could prove to be attractive
targets for therapeutic development. This hypothesis is supported by a number of chemical and genetic validation studies.
Additionally, the peculiar biochemistry of many of the components, along with limited protein sequence identity emphasizes
the likelihood of developing compounds that selectively inhibit the parasite enzymes. In this review, we examine the
status of target validation at the genetic and/or chemical levels from the protozoan parasites. While the proteins from some
species have been interrogated to the point that well-defined lead compounds have been identified with activities against
both enzyme and parasite growth, progress in other systems has to date been limited.